Medpace Holdings, Inc. $MEDP Shares Sold by US Bancorp DE

US Bancorp DE decreased its position in Medpace Holdings, Inc. (NASDAQ:MEDP) by 11.5% in the second quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 6,535 shares of the company’s stock after selling 853 shares during the period. US Bancorp DE’s holdings in Medpace were worth $2,051,000 at the end of the most recent quarter.

Other institutional investors and hedge funds also recently added to or reduced their stakes in the company. Geneos Wealth Management Inc. increased its holdings in Medpace by 64.9% in the first quarter. Geneos Wealth Management Inc. now owns 94 shares of the company’s stock valued at $29,000 after buying an additional 37 shares in the last quarter. Brooklyn Investment Group increased its holdings in Medpace by 244.8% in the first quarter. Brooklyn Investment Group now owns 100 shares of the company’s stock valued at $30,000 after buying an additional 71 shares in the last quarter. Whittier Trust Co. increased its holdings in Medpace by 47.3% in the first quarter. Whittier Trust Co. now owns 109 shares of the company’s stock valued at $33,000 after buying an additional 35 shares in the last quarter. Bank Julius Baer & Co. Ltd Zurich purchased a new position in Medpace in the first quarter valued at $60,000. Finally, Assetmark Inc. increased its holdings in Medpace by 24.9% in the first quarter. Assetmark Inc. now owns 216 shares of the company’s stock valued at $66,000 after buying an additional 43 shares in the last quarter. Hedge funds and other institutional investors own 77.98% of the company’s stock.

Medpace Trading Down 0.5%

Shares of NASDAQ MEDP opened at $514.32 on Thursday. Medpace Holdings, Inc. has a 12-month low of $250.05 and a 12-month high of $547.15. The stock has a market cap of $14.45 billion, a PE ratio of 38.24, a P/E/G ratio of 3.24 and a beta of 1.40. The company has a 50-day moving average of $488.51 and a 200 day moving average of $378.75.

Medpace (NASDAQ:MEDP) last announced its quarterly earnings data on Monday, July 21st. The company reported $3.10 earnings per share (EPS) for the quarter, beating the consensus estimate of $3.00 by $0.10. Medpace had a net margin of 18.74% and a return on equity of 67.66%. The company had revenue of $603.31 million during the quarter, compared to analysts’ expectations of $537.70 million. During the same quarter in the prior year, the company earned $2.75 EPS. Medpace’s revenue was up 14.2% compared to the same quarter last year. Medpace has set its FY 2025 guidance at 13.760-14.53 EPS. On average, sell-side analysts forecast that Medpace Holdings, Inc. will post 12.29 EPS for the current fiscal year.

Analyst Ratings Changes

A number of research analysts have weighed in on the stock. Robert W. Baird lifted their price objective on shares of Medpace from $313.00 to $490.00 and gave the company a “neutral” rating in a report on Wednesday, July 23rd. Rothschild Redb cut shares of Medpace from a “strong-buy” rating to a “hold” rating in a research note on Wednesday, September 3rd. Rothschild & Co Redburn cut shares of Medpace from a “buy” rating to a “neutral” rating and boosted their target price for the stock from $342.00 to $474.00 in a research note on Wednesday, September 3rd. Barclays boosted their target price on shares of Medpace from $300.00 to $450.00 and gave the stock an “equal weight” rating in a research note on Wednesday, July 23rd. Finally, TD Cowen reissued a “sell” rating and set a $366.00 target price (up previously from $283.00) on shares of Medpace in a research note on Wednesday, July 23rd. Two equities research analysts have rated the stock with a Buy rating, twelve have given a Hold rating and three have issued a Sell rating to the stock. According to data from MarketBeat, the stock presently has a consensus rating of “Reduce” and a consensus price target of $424.10.

Insider Buying and Selling

In other Medpace news, President Jesse J. Geiger sold 41,801 shares of the business’s stock in a transaction dated Thursday, July 24th. The shares were sold at an average price of $453.11, for a total value of $18,940,451.11. Following the transaction, the president directly owned 36,503 shares in the company, valued at $16,539,874.33. The trade was a 53.38% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through the SEC website. Also, General Counsel Stephen P. Ewald sold 3,000 shares of the business’s stock in a transaction dated Monday, July 28th. The shares were sold at an average price of $450.00, for a total transaction of $1,350,000.00. Following the completion of the transaction, the general counsel owned 10,343 shares in the company, valued at $4,654,350. The trade was a 22.48% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 161,266 shares of company stock worth $74,111,427 over the last ninety days. 20.30% of the stock is currently owned by insiders.

About Medpace

Medpace Holdings, Inc engages in the provision of outsourced clinical development services to the biotechnology, pharmaceutical and medical device industries. Its services include medical department, clinical trial management, data-driven feasibility, study-start-up, clinical monitoring, regulatory affairs, patient recruitment and retention, medical writing, biometrics and data sciences, pharmacovigilance, core laboratory, laboratories, clinics, and quality assurance.